Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9716658 | 0.87 | LMNA (0.82) | LMNATDP1ALDH1A1CAPN1POLB | |
| SCHEMBL31390220 | 0.87 | LMNA (0.82) | LMNATDP1ALDH1A1CAPN1POLB | |
| SCHEMBL9716661 | 0.87 | LMNA (0.82) | LMNATDP1ALDH1A1CAPN1POLB | |
| SCHEMBL9556460 | 0.87 | ADORA2A (0.58) | LMNATDP1ALDH1A1MAPK1ADORA2A | |
| SCHEMBL5612699 | 0.85 | LMNA (0.73) | LMNATDP1ALDH1A1HSD17B10PSMB5 | |
| SCHEMBL9234559 | 0.85 | LMNA (0.73) | LMNATDP1ALDH1A1HSD17B10PSMB5 | |
| SCHEMBL10665563 | 0.85 | LMNA (0.73) | LMNATDP1ALDH1A1HSD17B10PSMB5 | |
| SCHEMBL9232060 | 0.84 | LMNA (0.76) | LMNATDP1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL9232064 | 0.84 | LMNA (0.76) | LMNATDP1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL7778087 | 0.83 | LMNA (0.71) | LMNATDP1ALDH1A1HSD17B10PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | LMNA 3012/4885TDP1 1175/4885ALDH1A1 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.